1. The treatment of cervical intraepithelial neoplasia includes the following.
(1) observation and follow-up.
(2) freezing, laser, electrocoagulation.
(3) circumferential electrodesiccation
(4) cervical conization
(5) hysterectomy
(6) drugs, HVP vaccine
(7) photodynamic therapy.
(8) Pharmacological treatment.
2. Drugs for the treatment of cervical lesions are broadly divided into three types.
(1) immunomodulators, (such as human recombinant gamma-interferon, beta-interferon, oral isotretinoin (pau d’arco), imiquimod, Iscador QuS, and interferon A, etc.)
(2) Recombinant viral vaccines that produce deliberate cytotoxic effects on HPV-infected cells, thereby eliminating HPV infection and CIN.
(3) Anti-inflammatory drugs, which treat inflammation and HPV infection associated with cervical intraepithelial neoplasia by eliminating protozoa, mycobacteria and microorganisms from the reproductive tract.
3.Drug treatment
As drug therapy for cervical intraepithelial neoplasia is still in the research and trial stage, the clinical value is yet to be determined and cannot be recommended as routine treatment. HPV vaccine research has shown good momentum and promise and is expected to be a breakthrough in drug therapy for cervical intraepithelial neoplasia.
HPV Vaccine
20million Americans and approximately 630million worldwide will be infected with HPV. 2.6 million new infections will occur each year in the United States.
HPV infection rates are highest among sexually active women under the age of 25.
Among young women who are HPV negative, 32% will first become infected with HPV within 24 months and 43% will become infected at 36 months.
About 1/3 or more of men and women who are sexually active will be infected with HPV at least once in all.
Two HPV vaccines are available.
(1) MERCK: 4-valent HPV vaccine (GARDASIL)
FDA has approved for marketing in the United States.
(2) GSK: The 2-valent HPV vaccine is pending approval in the EU and the SDA in China.
Both vaccines are prophylactic and have no therapeutic effect on people with existing HPV infection.